Hola,
Are you new here?

NEOSETAC

financed

New Selenium based Targeted Nanocapsules to treat Breast Cancer

The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer... see more

31/10/2023

UAB

504K€

Project Budget: 504K€

Project leader

UNIVERSITAT AUTÒNOMA DE BARCELONA No se ha especificado una descripción o un objeto social para esta compañía.

total researchers 1270

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 9 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2023-10-31

MSCA-RISE-2017: Research and Innovation Staff Excha... Objective:The RISE scheme will promote international and inter-sector collaboration through research...

I+D

Cerrada does 8 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

UAB

202.50K€ | Leader

94.37K€ | participant

CLINISCIENCES

22.50K€ | participant

RETE EUROPEA DELL'INNOVAZION...

67.50K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 72 months Date Start: 2017-10-02
End date: 2023-10-31

Project leader

UNIVERSITAT AUTÒNOMA DE BARCELONA No se ha especificado una descripción o un objeto social para esta compañía.

total researchers 1270

Project Budget 504K€

participation deadline Sin fecha límite de participación.

Project description The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women, causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers